Ezetimibe to prevent irregular heartbeat after ablation for atrial fibrillation
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether taking a cholesterol-lowering medicine called ezetimibe alongside the usual care can help prevent atrial fibrillation from coming back after a procedure called catheter ablation. Catheter ablation is a treatment that uses heat or cold to destroy tiny areas of heart tissue that cause irregular heartbeats. For people with persistent atrial fibrillation, this trial may offer a way to improve the long-term success of the ablation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of atrial fibrillation called 'persistent' and are scheduled for your first catheter ablation.
- You have never had a catheter ablation for atrial fibrillation before.
- You have not had a heart attack or stroke in the last 3 months.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an early procedure (catheter ablation) for atrial fibrillation (AF) can prevent strokes in people with a high risk of stroke. The goal is to see if this treatment is safer and more effective than standard care for patients with other health conditions.
This trial tests if enavogliflozin, a diabetes drug, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people with heart failure. If you've recently had or are planning this procedure, this study may offer a new way to keep your heart rhythm steady.
This trial tests whether a catheter procedure that treats atrial fibrillation works better than standard care for people with heart failure with preserved ejection fraction. It aims to improve heart rhythm symptoms and overall outcomes compared with conventional treatment.
This trial tests whether a weight-loss medication called tirzepatide (given as a shot) helps prevent atrial fibrillation from coming back after a catheter ablation procedure. It is for people who have both obesity and atrial fibrillation, and it may help improve heart health by reducing weight and inflammation.
This study tests advanced technology to improve how atrial fibrillation (AFib) is treated with a heart ablation procedure. It may help patients who are already advised to have AFib ablation by seeing how well the approach works in real clinical practice.
This trial tests whether early catheter ablation (a procedure to fix irregular heartbeats) helps people who have both heart failure and atrial fibrillation. It looks at how this treatment affects your heart function and quality of life.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.